The invention a thrombolytic drug based on cobra venom PIIII type metalloproteinase which is obtained by separating and purifying venom of Chinese cobra or Naja cobra with a class name of Naja atra. The metalloproteinase is singe strand glycoprotein, structural analysis shows that the metalloproteinase has three structural domains, namely a metalloproteinase structural domain, a disintegrin structural domain and a cysteine-rich structural domain and belongs to PIIII type metalloproteinase with names of Atrase A and Atrase B. A sequence of the Atrase A is SEQ ID No.1, and a sequence of the Atrase B is SEQ ID No.2. Target protein and the thrombolytic drug can induce endogenous fibrinolytic enzyme activator tPA release so as to play a thrombolytic role, and the thrombolytic drug can be used for thrombolytic treatment of thrombotic diseases.